Sepsis is a systemic inflammatory response syndrome to infection. Human b-defensin 1 (DEFB1) is a multifunctional mediator in infection and inflammation, which has been largely explored in ex vivo studies. The present case-control study was designed to investigate whether DEFB1 genomic variations are associated with the susceptibility to and the outcome of severe sepsis in 211 patients with severe sepsis and 157 ethnic-matched healthy controls. After correcting for multiple testing, the À44G/C was the only polymorphism found to show significant associations with both the susceptibility to and the fatal outcome of severe sepsis (P ¼ 0.0049, odd ratio (OR) 1.971 and P ¼ 0.002, OR 2.406, respectively). Haplotype À20A/À44C/À52G showed a protective role against severe sepsis (P ¼ 0.0066, OR 0.6751), whereas haplotype À20G/À44G/À52G served as a risk factor for the fatal outcome of severe sepsis (P ¼ 0.0052, OR 2.427). These findings provide further evidence that b-defensin 1 may play a role in the pathogenesis of severe sepsis.
Introduction
Sepsis is an infection-initiated systemic inflammatory reaction syndrome resulting from the interactions between environmental and genetic factors. 1, 2 Studies confirmed that single nucleotide polymorphisms (SNPs) in some particular genes, such as tumor necrosis factor locus, interleukin-1 receptor antagonist, plasminogen activator inhibitor-1 and so on, play a critical role in sepsis. 3, 4 Defensins are cysteine-rich cationic antimicrobial polypeptides with three disulfide bridges and are expressed in plants, insects and mammals. 5, 6 Human bdefensin 1 (DEFB1, hBD-1) was the first characterized human b-defensin identified in hemofiltrate. 7 DEFB1 is constitutively expressed mainly in kidney, keratinocytes, oral cavity, as well as in urogenital tract. 8, 9 The in vitro expression of DEFB1 can be upregulated by LPS, IL-1b, interferon-g (IFN-g) and arginine. [10] [11] [12] In vivo, elevated levels of DEFB1 in body fluid were observed in individuals suffering from sepsis and infectious diseases. 13, 14 Moreover, the inducible expression of DEFB1 showed interindividual variability upon infection or LPS stimulation. 10, 15 In addition, DEFB1 has shown chemoattractant properties for dendritic cells and memory T cells via chemokine receptor CCR6, which links innate and adaptive immunity. 16 Evidence suggests that DEFB1 may play an important role during the course of infection as well as inflammation. 15, 17, 18 The cluster of human defensin genes including adefensin genes and at least four b-defensin genes is located in chromosome 8p22-23. 5 This region containing a number of genes related to the innate immunity and the nervous system shows a strikingly high polymorphic rate in the human population. 19 Recent studies found that the genes coding a-defensins 1 (DEFA1) and 3 (DEFA3) as well as b-defensins 2 (DEFB4), 3 (DEFB103) and 4 (DEFB104) exhibit copy number polymorphisms, while the DEFB1 gene was a single copy gene containing several SNPs. [20] [21] [22] [23] The SNPs in DEFB1 have been associated with the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) as well as infectious disease. [24] [25] [26] [27] [28] However, the genetic predisposition of individuals carrying these SNPs to sepsis remains unknown. Hence, the present study was designed to investigate the association of genomic variants within DEFB1 and severe sepsis.
Results
All the enrolled patient and controls were Han Chinese. In patients with severe sepsis, 46.9% individuals have experienced surgical or traumatic history. Severe acute pancreatitis (18.5%) was the most frequent initial diagnosis, followed by gastrointestinal perforation or intestinal fistula after abdominal operation (17.5%), pneumonia (17.1%), trauma (14.2%) and biliary duct or liver infection (10.4%). While lung (42.6%), abdomen (19.9%) and blood (17.5%) were the main source of infection. For treatment of severe sepsis, surgical interventions were applied for 44.5% patients. Meanwhile, broad-spectrum antibiotics were widely used in all the patients. The most commonly administered antibiotics were Tienam (Imipenem plus Cilastatin, 40.3% patients), Sulperazon (Sulbactam plus Cefoperazone, 39.8% patients), Vancocin (Vancomycin Hydrochloride for intra venous, 33.2% patients) and Tazocin (Piperacillin, 28.9% patients). Antifungal agents were used in 37.4% patients.
The allele frequency and genotype frequency of the two groups were shown in Table 1 . Of note, the mutant allele (A allele) of SNP 1654G/A, which had been reported in another study, 27 was not detected in the present cohorts. The genotype-allele distribution for the assayed loci followed Hardy-Weinberg equilibrium in both patients and controls (P40.05). After correcting for multiple testing, the frequency of À44G allele in patients with severe sepsis was significantly higher than that in controls (15.64 vs 8.60%; P ¼ 0.0049, OR 1.971, 95% CI 1.227-3.166). Furthermore, in severe septic patients, the frequency of À44G-allele was 20.91% in non-survivors, while it was 9.90% in survivors (P ¼ 0.002, OR 2.406, 95% CI 1.368-4.232). The logistic regression model including age and gender as covariates confirmed the above associations (Po0.05, OR 1.735, 95% CI 1.030-2.958 and Po0.05, OR 2.741, 95% CI 1.128-6.660, respectively).
Linkage disequilibrium (LD) analysis showed that SNPs À52A/G, À44C/G and À20A/G were in strong LD. Three most common haplotypes were found in the cohort ( Table 2 ). The haplotype À20G/À44G/À52G was more frequent in non-survivors than in survivors (17.1 vs 7.7%; P ¼ 0.0052, OR 2.427, 95% CI 1.307-4.507). However, the frequency of haplotype À20A/À44C/À52G in control and severe sepsis group was 41.7 and 32.0%, respectively (P ¼ 0.0066, OR 0.6751, 95% CI 0.4850-0.8902).
Discussion
In this study, the À44G/C variation was associated with both the susceptibility to and the fatal outcome of severe sepsis. Furthermore, the À20G/À44G/À52G haplotype was associated with the fatal outcome of severe sepsis, whereas the À20A/À44C/À52G haplotype showed a protective role against severe sepsis. To our knowledge, this is the first association study to investigate the genetic impact of DEFB1 polymorphisms on sepsis. 
SNPs
Severe sepsis (n ¼ 211) Defensins are a family of secreted antimicrobial peptides that directly interfere with bacterial membranes. In addition, defensins have been implicated in the regulation of various inflammatory and immunological processes. 5, 6 In vitro, b-defensin peptides showed protective action against LPS-mediated effects via abolishing induction of mitogen-activated protein kinase. 29 Elucidation of the pathophysiological role of the human b-defensin 1 peptide in infectious and inflammatory diseases such as sepsis needs to be confirmed in an additive genetic animal model. Since the members of the defensin family have overlapping effect, a single gene knockout model will compromise the investigation of the biologic role of the target gene. Disruption of the entire defensin gene cluster is hampered by currently available techniques. 5 Meanwhile, human defensins and their homologues in animals may not be completely equivalent either in structure or in function. 5, 6 The lack of fully representative animal models increases the importance of analysis of the impact of defensin gene polymorphisms on human health.
Previous studies have shown that the inducible mRNA level of DEFB1 appeared as interindividual variability, 10 and production of human b-defensin 1 peptide was genetically regulated. 30 The À44C/G variation, which was located in the 5 0 -UTR of DEFB1, has been implicated in the pathogenesis of infections with HIV and Candida. 24, 28 In this study, it is noteworthy that, even with a standard Bonferroni correction for multiple tests on the five SNPs and three haplotypes, the P-values for the association of À44G/C and haplotype À20G/À44G/À52G as well as haplotype À20A/À44C/À52G with related phenotypes are still significant. This strongly supports the significance of the present findings. Using reporter gene constructs analysis, a very recent study demonstrated that the À44G/ C polymorphism did influence the promoter activity of DEFB1, 30 which may lead to a variation in transcription or translation of DEFB1, or in stability of DEFB1 mRNA. Therefore, individuals carrying different alleles at À44 loci of DEFB1 may show different host immune response to infection and ultimately influence the pathophysiological course of sepsis.
Previous studies have reported a protective role of À44C-G SNP in HIV infection and oral Candida infection in Caucasian. 24, 28 However, the present study found that the À44C-G SNP was a risk factor for incidence and fatal outcome of severe sepsis in Han Chinese. Such conflicting results have been reported in another genetic association study of DEFB1 polymorphisms and asthma. 26 The discrepancy may be contributed by ethnic distribution, target disease studied and other unmeasured covariates. Since sepsis is a polygenic syndrome, it is unlikely that a single polymorphism would result in a particular phenotype of sepsis. The DEFB1 gene is located on chromosome 8p22-23 which contains a cluster of a-defensin and b-defensin genes. These defensins display important biological functions in immune response to infection and inflammation. 5, 6 DEFB4-encoding hBD-2 peptide shows high Gramnegative antimicrobial activity, while DEFB103-encoding hBD-3 peptide is more effective on Gram-positive bacteria. 5, 6 Furthermore, defensins mediated adaptive immune response via Toll-like receptor. 5 Meanwhile, in vivo study showed a protective role of overexpressed bdefensin 2 against sepsis via anti-inflammation activity. 31 Studies have shown that DEFB4 and DEFB103 as well as DEFB104 were polymorphic in copy number variation, [20] [21] [22] and the genomic copy number of DEFB4 correlated with the level of its transcript. 20 Copy number polymorphism of defensin may have a crucial role in inflammatory disease, which has been demonstrated in Crohn's disease. 32 Therefore, the functional SNP À44C/ G and the related haplotypes within the DEFB1 gene in this study, as in any genetic association study, may not be causative but may be in strong linkage disequilibrium with separate causative polymorphisms such as copy number polymorphisms in other defensin genes. The À44C-G SNP in DEFB1 may be in synergy with these defensins or other immune components to modulate host immune response. Further associated studies should address the role of defensin copy number polymorphisms in the pathogenesis of sepsis.
The current study used three different methods for genotyping. Since À52A/G, À44C/G and À20A/G variations are located very closely, sequencing is the best way for the primary measurement. Meanwhile, PCR-allele-specific amplification (PCR-ASA) was adopted for detection of À390A/T for financial reason. Further genetic epidemiological studies or clinical application for assay development using the standard method (sequencing or TaqMan assay) should be implemented.
On the basis of a well-matched case-control association study, the present investigation identified that DEFB1 genetic polymorphisms were not only associated with susceptibility to severe sepsis, but also related to the clinical course of severe sepsis. These findings suggest that DEFB1 is involved in immune response central to the pathophysiology of severe sepsis. Consistent with this view were the findings indicating that defensins did suppress the release of proinflammatory cytokines and adhesion molecules in vivo. 29, 31 Thus, DEFB1 could both play a direct antimicrobial role and have a modulating effect on the inflammatory response. In summary, DEFB1 plays an important role in the host immune response to severe sepsis. The genomic variation À44G/C within DEFB1 showed a positive association with the development of severe sepsis. Further studies correlating À44G/C variation with level of human b-defensin 1 peptide in serum and a replicate association design with samples from other ethnicities to confirm the reported findings are currently going on.
Subjects and methods
After the study was approved by the local Ethics Committee, informed written consent was obtained from all subjects or a first degree relative of the patient. A total of 211 patients with severe sepsis (123 men and 88 women, age 60.6717.5 years) and 157 ethnic-matched healthy controls (96 men and 61 women, age 58.4718.3 years) were enrolled in the study. All the subjects were Han Chinese. The diagnosis of sepsis and severe sepsis met the criteria recommended by the American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference. 33 Patients with immunosuppression or AIDS were excluded.
Genomic DNA was extracted from peripheral whole blood and used as a template for next analysis. The SNPs À1816A/G (rs2741136), À52A/G (rs1799946), À44C/G (rs1800972) and À20A/G (rs11362) were analyzed using standard direct sequencing. The À390A/T (rs2738182) variation was assayed by mean of PCR-ASA. The polymorphism 1654G/A (rs2738047) was detected using TaqMan assay. The genotypes of 30 randomly selected samples were confirmed by a second method.
All SNPs data were evaluated for Hardy-Weinberg equilibrium. Allele frequency and genotype frequency between the defined groups were compared using Fisher's exact test or w 2 -test. Logistic regression was used to model the effect of the related genotype on incidence and outcome of severe sepsis when gender and age were included as covariates. Linkage disequilibria and haplotype were analyzed using the Haploview 2.05 program. The Bonferroni method was used to correct for multiple comparisons where applicable. Po0.05 was considered statistically different.
